Floatz logo

DULAGLUTIDE

Type 2 Diabetes

Brigham and Women's Hospitalprotein_peptidePhase 4 / ApprovedActive
BB
66/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
61/ 100
Competitive Position
73/ 100

Competitive context

141 Active assets in the Type 2 Diabetes cohort.

Asset / SponsorPhaseRating
Semaglutide
Shanghai Jiao Tong University School of Medicine
Phase 4BBB
Liraglutide
RenJi Hospital
Phase 4BBB
Cotadutide
AstraZeneca
Phase 2BBB
Dapagliflozin
Bhavya Bhavya, MD
Phase 4BBB
Exenatide
Vivani Medical, Inc
Phase 4BBB

View all 50 →

Same molecule, other indications

DULAGLUTIDE is also rated in:

glucose intoleranceDormant
BBB
Indicative ·
75 / 100
View asset →
glucose intoleranceDormant
BB
Indicative ·
69 / 100
View asset →
metabolic dysfunction-associated steatotic liver diseaseDormant
BB
Indicative ·
65 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →